Monomethyl Fumarate
Brand names: Bafiertam · Active ingredient: Monomethyl Fumarate
In short: BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
What is Monomethyl Fumarate used for?
BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Monomethyl Fumarate dosage
Obtain the following prior to treatment with BAFIERTAM:
A complete blood cell count (CBC), including lymphocyte count .
Serum aminotransferase, alkaline phosphatase, and total bilirubin levels .
The starting dosage for BAFIERTAM is 95 mg twice a day orally for 7 days. After 7 days, the dosage should be increased to the maintenance dosage of 190 mg (administered as two 95 mg capsules) twice a day orally. Temporary dosage reductions to 95 mg twice a day may be considered for individuals who do not tolerate the maintenance dosage. Within 4 weeks, the recommended dosage of 190 mg twice a day should be resumed. Discontinuation of BAFIERTAM should be considered for patients unable to tolerate return to the maintenance dosage. Administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to BAFIERTAM dosing, may reduce the incidence or severity of flushing .
Swallow BAFIERTAM capsules whole and intact. Do not crush, chew, or mix the contents with food. BAFIERTAM can be taken with or without food.
Obtain a complete blood cell count (CBC), including lymphocyte count, 6 months after initiation of BAFIERTAM and then every 6 to 12 months thereafter, as clinically indicated .
Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels during treatment with BAFIERTAM, as clinically indicated .
How to take Monomethyl Fumarate — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Dosage
Inform patients that they will be provided one strength of BAFIERTAM when starting treatment: take one capsule for the 7 day starter dose and two capsules for the maintenance dose, both to be taken twice daily. Inform patients to swallow BAFIERTAM capsules whole and intact. Inform patients to not crush, chew, or mix capsule contents with food. Inform patients that BAFIERTAM can be taken with or without food .
Anaphylaxis and Angioedema
Advise patients to discontinue BAFIERTAM and seek medical care if they develop signs and symptoms of anaphylaxis or angioedema .
Progressive Multifocal Leukoencephalopathy
Inform patients that progressive multifocal leukoencephalopathy (PML) has occurred in patients who received dimethyl fumarate (the prodrug of monomethyl fumarate). Inform the patient that PML is characterized by a progression of deficits and usually leads to death or severe disability over weeks or months. Instruct the patient of the importance of contacting their healthcare provider if they develop any symptoms suggestive of PML. …
Warnings & precautions
Do not take this medicine if: BAFIERTAM is contraindicated in patients:
with known hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or to any of the excipients of BAFIERTAM. Reactions may include anaphylaxis or angioedema. .
taking dimethyl fumarate or diroximel fumarate .
BAFIERTAM can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms in patients taking dimethyl fumarate (the prodrug of BAFIERTAM) have included difficulty breathing, urticaria and swelling of the throat and tongue. Patients should be instructed to discontinue BAFIERTAM and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema.
Progressive multifocal leukoencephalopathy (PML) has occurred in patients with MS treated with dimethyl fumarate (the prodrug of BAFIERTAM). PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received dimethyl fumarate for 4 years while enrolled in a clinical trial. During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5x109/L for 3.5 years) while taking dimethyl fumarate . The patient had no other identified systemic medical conditions resulting in compromised immune system function and had not previously been treated with natalizumab, which has a known association with PML. The patient was also not taking any immunosuppressive or immunomodulatory medications concomitantly.
PML has also occurred in patients taking dimethyl fumarate in the postmarketing setting in the presence of lymphopenia (<0.9x109/L). …
Monomethyl Fumarate side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Anaphylaxis and Angioedema
Progressive Multifocal Leukoencephalopathy
Herpes Zoster and Other Serious Opportunistic Infections
Lymphopenia
Liver Injury
Flushing
Serious Gastrointestinal Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in the following sections were obtained using dimethyl fumarate delayed-release capsules (the prodrug of BAFIERTAM).
Adverse Reactions in Placebo-Controlled Trials with Dimethyl Fumarate
In the two well-controlled studies demonstrating effectiveness, 1529 patients received dimethyl fumarate with an overall exposure of 2244 person-years .
The adverse reactions presented in
Table 1
below are based on safety information from 769 patients treated with dimethyl fumarate 240 mg twice a day and 771 placebo-treated patients. The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea. …
Drug interactions
Both dimethyl fumarate and diroximel fumarate are metabolized to monomethyl fumarate. Therefore, BAFIERTAM is contraindicated in patients currently taking dimethyl fumarate or diroximel fumarate. BAFIERTAM may be initiated the day following discontinuation of either of these drugs.
About this medicine
BAFIERTAM contains the active ingredient monomethyl fumarate, which is an unsaturated monomethyl ester. It is also known by its chemical name, fumaric acid monomethyl ester, (C5H6O4). It has the following structure:
Monomethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 130.10.
BAFIERTAM is provided as soft gelatin delayed-release capsules for oral administration, containing 95 mg of monomethyl fumarate consisting of the following inactive ingredients:
Glyceryl caprylate/caprate, lactic acid, polyoxyl 40 hydrogenated castor oil and povidone K30. The capsule shell, printed with black ink, contains the following inactive ingredients: ammonium hydroxide, butyl alcohol, ferrosoferric oxide, isopropyl alcohol, gelatin, propylene glycol, shellac, solution of sorbitans and sorbitol and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a161f9d4-70f1-4097-957a-eafb35d3274f. Read the full official label on DailyMed.